Work

Phase I study of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions every 28 days in patients with solid tumors

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.2513

Authors: M. J. Robertson, J. M. Kirkwood, T. Logan, H. M. Blair, J. R. Weisenbach, J. M. Shipe-Spotloe, L. Kirby, L. Thurmond, M. M. Dar, P. T. Ho

Institution: University of Pittsburgh

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2222886792

Cites:

Cited by: 7

Related to: 10